Jeroen drives the strategic deployment of Semarion’s cell assaying solutions across drug discovery through product commercialisation and partnering.

Previously, he developed cell model for neuro-inflammation and worked with drug-delivery systems, RNAi, and stem cell therapeutics.

Tarun drives the innovation of the SemaCyte® technology platform through novel material design and engineering that is embedded across Semarion’s product suite.

His background spans running microchip fabrication processes in industry to developing an advanced nanomagnetic therapy for glioblastoma.

Serena leads the development and testing of the Semarion’s products to ensure seamless integration for drug discovery workflows.

She has a decade of experience of academic and industry research in oncology, stem cell biology, haematology, and ophthalmology.

Daniel’s work is focussed on developing key applications for the SemaCyte® platform to accelerate cell biology research and cancer drug discovery.

His previous research activities include DNA replication and the DNA damage response, alongside cancer target identification and validation.

Tom heads Semarion’s microfabrication process development and optimisation with a focus on high yield, scalable manufacturing.

He has worked in both industrial and academic settings on development and fabrication projects for advanced materials.

Blaise is part of Semarion’s cell biology team where she works to develped and evaluate novel applications, e.g. in oncology or neuroscience.

Previously, she did her PhD at King’s College in London where she engineered microenvironments to guide stem cell differentiation.

Holly is part of Semarion’s advanced materials team where she works to fabricate SemaCytes and develop novel technology features.

Previously, she did her PhD at the Universitry of Cambridge where she designed novel magnetic sensors for biomedical applications.

Paul manages the Board and guides the Executive Team on partnering and business development.

He is Chief Business Officer at Mission Therapeutics. Paul has been involved in several trade sales and has executed over $4.5B worth of outlicensing partnerships including the hepatitis C protease inhibitor, Olysio®.

Karolina is an Investment Manager at Parkwalk Advisors, specialised in Healthcare and Life Sciences.

She has over a decade of experience building life sciences and healthcare companies within the Cambridge Cluster. In 2018 she co-founded and successfully delivered the first life sciences startup accelerator in Cambridge with a portfolio value of over £90m. Karolina completed a PhD in protein folding from the University of Cambridge and carried out a drug development postdoc work at MedImmune/AstraZeneca.

Fatima is an Investment Manager at Cambridge Seed Funds, focussed on delivering impact from research at the University of Cambridge.

Through her roles at the CRUK, the Babraham Institute, and Oxford University she developed experience in innovation management and business development.

Russell is Professor of Experimental Physics (Cambridge University) and supports the development of the SemaCyte® platform.

His research career has focused on nanomagnetism, nanotechnology, and optics. He is a Fellow of the Royal Society and the Founder of Durham Magneto Optics.

Del is a NED and provides key industry insight on product and application development for the SemaCyte® platform.

Del co-founded Essen Biosciences and spearheaded the commercial development of the Incucyte® platform. He is also a Technology scout at Sartorius, and a NED at Axol Biosciences and ELRIG.

Jacqui is a Human Resources consultant specialising in providing advice and support to start-up and early stage biotech and high-tech SME’s.

Covering all aspects of Human Resources management, her in-house experience has been gained primarily in pharmaceutical, medical devices and pharma services companies, having held UK, Europe-wide and global roles.

Peter is an Investment Director at Martlet Capital, with a focus on early-stage life science investments.

As a former co-founder and General Partner of SV Health Investors, he brings a career background in institutional life sciences venture capital, combined with university technology commercialisation experience.